While in female GII-III patients we did not observe differences depending on the expression of PRLR, there was a substantial decrease in the survival of female GBM patients with PRL+/PRLRLOW vs. PRL+/PRLRHIGH, i.e. 6.6 mos. This evidence concerns the gene PRLR and glioblastoma.